{"id":"https://openalex.org/W2897380487","doi":"https://doi.org/10.25756/rpf.v10i1.147","title":"Adalimumab in the treatment of moderate-severe hidradenitis suppurativa: a cost-effectiveness analysis","display_name":"Adalimumab in the treatment of moderate-severe hidradenitis suppurativa: a cost-effectiveness analysis","publication_year":2017,"publication_date":"2017-05-10","ids":{"openalex":"https://openalex.org/W2897380487","doi":"https://doi.org/10.25756/rpf.v10i1.147","mag":"2897380487"},"language":"en","primary_location":{"id":"pmh:oai:doaj.org/article:ecce632b3fea4ea28187d73c74d40553","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/ecce632b3fea4ea28187d73c74d40553","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Revista Portuguesa de Farmacoterapia, Vol 10, Iss 1 (2018)","raw_type":"article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["datacite","doaj"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://doi.org/10.25756/rpf.v10i1.147","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110018362","display_name":"Sofia Borges","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405255806","display_name":"AbbVie (Portugal)","ror":"https://ror.org/03em9qx04","country_code":"PT","type":"company","lineage":["https://openalex.org/I2948539688","https://openalex.org/I4405255806"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Borges, Sofia","raw_affiliation_strings":["AbbVie Portugal, Amadora, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Portugal, Amadora, Portugal","institution_ids":["https://openalex.org/I4405255806"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112907350","display_name":"Nuno Menezes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210141686","display_name":"Centro Hospitalar de Vila Nova de Gaia","ror":"https://ror.org/042jpy919","country_code":"PT","type":"healthcare","lineage":["https://openalex.org/I4210141686"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Menezes, Nuno","raw_affiliation_strings":["Hospital de Vila Nova de Gaia, Vila Nova de Gaia, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital de Vila Nova de Gaia, Vila Nova de Gaia, Portugal","institution_ids":["https://openalex.org/I4210141686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024117292","display_name":"Catarina Oliveira Silva","orcid":"https://orcid.org/0000-0002-5447-0644","observed_orcids":["https://orcid.org/0000-0002-5447-0644","https://orcid.org/0000-0002-5077-5176"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Silva, Catarina","raw_affiliation_strings":["Eurotrials-Scientific Consultants, Lisboa/CISP, ENSP, Lisboa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eurotrials-Scientific Consultants, Lisboa/CISP, ENSP, Lisboa","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077025645","display_name":"Tiago Ribeiro Torres","orcid":"https://orcid.org/0000-0003-0404-0870","observed_orcids":["https://orcid.org/0000-0003-0404-0870"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Torres, Tiago","raw_affiliation_strings":["Centro Hospitalar e Universit\u00e1rio do Porto, Porto, Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro Hospitalar e Universit\u00e1rio do Porto, Porto, Portugal","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"1","first_page":"22","last_page":"37"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12731","display_name":"Hidradenitis Suppurativa and Treatments","score":0.9672999978065491,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12731","display_name":"Hidradenitis Suppurativa and Treatments","score":0.9672999978065491,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.03139999881386757,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12328","display_name":"Autoimmune and Inflammatory Disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":0.9789999723434448},{"id":"https://openalex.org/keywords/hidradenitis-suppurativa","display_name":"hidradenitis suppurativa","score":1.0},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9509999752044678},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.7639999985694885},{"id":"https://openalex.org/keywords/tnf-alpha-inhibitors","display_name":"TNF-alpha inhibitors","score":0.6499999761581421},{"id":"https://openalex.org/keywords/supportive-care","display_name":"supportive care","score":0.777999997138977},{"id":"https://openalex.org/keywords/markov-model","display_name":"Markov model","score":0.8019999861717224},{"id":"https://openalex.org/keywords/indirect-costs","display_name":"indirect costs","score":0.5239999890327454}],"concepts":[{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.7947810888290405},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7463703155517578},{"id":"https://openalex.org/C64332521","wikidata":"https://www.wikidata.org/wiki/Q614165","display_name":"Quality-adjusted life year","level":3,"score":0.509545624256134},{"id":"https://openalex.org/C6964187","wikidata":"https://www.wikidata.org/wiki/Q659256","display_name":"Indirect costs","level":2,"score":0.45823031663894653},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.44008925557136536},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.4356027841567993},{"id":"https://openalex.org/C184834754","wikidata":"https://www.wikidata.org/wiki/Q358564","display_name":"Cost\u2013utility analysis","level":3,"score":0.42169928550720215},{"id":"https://openalex.org/C2779900020","wikidata":"https://www.wikidata.org/wiki/Q6015473","display_name":"Incremental cost-effectiveness ratio","level":4,"score":0.4175507128238678},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.14013442397117615},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.09017002582550049},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.07855823636054993},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0},{"id":"https://openalex.org/C121955636","wikidata":"https://www.wikidata.org/wiki/Q4116214","display_name":"Accounting","level":1,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"pmh:oai:doaj.org/article:ecce632b3fea4ea28187d73c74d40553","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/ecce632b3fea4ea28187d73c74d40553","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Revista Portuguesa de Farmacoterapia, Vol 10, Iss 1 (2018)","raw_type":"article"},{"id":"doi:10.25756/rpf.v10i1.147","doi":"https://doi.org/10.25756/rpf.v10i1.147","is_oa":true,"landing_page_url":"https://doi.org/10.25756/rpf.v10i1.147","pdf_url":null,"source":{"id":"https://openalex.org/S4306527858","display_name":"Revista portuguesa de farmacoterapia","issn_l":"1647-354X","issn":["1647-354X","2183-7341"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["vabb-shw"],"host_organization":"https://openalex.org/P4310318473","host_organization_name":"Formifarma, LDA.","host_organization_lineage":["https://openalex.org/P4310318473"],"host_organization_lineage_names":["Formifarma, LDA."],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},{"id":"mag:2897380487","doi":null,"is_oa":false,"landing_page_url":"http://revista.farmacoterapia.pt/index.php/rpf/article/view/147","pdf_url":null,"source":{"id":"https://openalex.org/S4306527858","display_name":"Revista portuguesa de farmacoterapia","issn_l":"1647-354X","issn":["1647-354X","2183-7341"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["vabb-shw"],"host_organization":"https://openalex.org/P4310318473","host_organization_name":"Formifarma, LDA.","host_organization_lineage":["https://openalex.org/P4310318473"],"host_organization_lineage_names":["Formifarma, LDA."],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Revista portuguesa de farmacoterapia","raw_type":null}],"best_oa_location":{"id":"doi:10.25756/rpf.v10i1.147","doi":"https://doi.org/10.25756/rpf.v10i1.147","is_oa":true,"landing_page_url":"https://doi.org/10.25756/rpf.v10i1.147","pdf_url":null,"source":{"id":"https://openalex.org/S4306527858","display_name":"Revista portuguesa de farmacoterapia","issn_l":"1647-354X","issn":["1647-354X","2183-7341"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["vabb-shw"],"host_organization":"https://openalex.org/P4310318473","host_organization_name":"Formifarma, LDA.","host_organization_lineage":["https://openalex.org/P4310318473"],"host_organization_lineage_names":["Formifarma, LDA."],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2587616834","https://openalex.org/W4200250376","https://openalex.org/W4417527128","https://openalex.org/W2891403154","https://openalex.org/W2940758956","https://openalex.org/W3094503269","https://openalex.org/W7168045932","https://openalex.org/W3165751676","https://openalex.org/W7172492366","https://openalex.org/W3092013173"],"abstract_inverted_index":{"Introduction:":[0],"To":[1],"assess":[2],"the":[3,11,126,148,155,181,194,261,268],"cost-effectiveness":[4,183,230,245,277],"of":[5,13,32,65,160,243,252],"adalimumab":[6,69,163,202],"versus":[7,70],"supportive":[8,71,167,223],"care":[9],"in":[10,36,108,125,170,278,282],"treatment":[12,205],"adults":[14],"with":[15,42,68],"active":[16],"moderate":[17],"to":[18,28,59,84,187],"severe":[19],"hidradenitis":[20],"suppurativa":[21],"who":[22],"have":[23],"had":[24],"an":[25],"inadequate":[26],"response":[27],"or":[29,52],"are":[30],"intolerant":[31],"conventional":[33],"systemic":[34],"therapy":[35],"Portugal.":[37],"Methods:":[38],"A":[39],"Markov":[40],"model":[41,156],"5":[43],"health":[44],"states":[45],"(high":[46],"response,":[47,48,50],"partial":[49],"non-response,":[51],"death)":[53],"and":[54,63,80,88,106,137,140,164,172,216,237,254,263,275],"4-week":[55],"cycles":[56],"was":[57,92,119,246],"developed":[58],"estimate":[60,85],"long-term":[61],"effectiveness":[62],"cost":[64,112,159],"treating":[66],"patients":[67,221],"care.":[72,224],"Data":[73],"from":[74,102,193],"head-to-head":[75],"clinical":[76],"trials":[77],"(PIONEER":[78],"I":[79],"II)":[81],"were":[82,100,144],"used":[83],"transition":[86],"probabilities":[87],"utilities.":[89],"Resource":[90],"use":[91],"characterized":[93],"by":[94,210,267],"Portuguese":[95,195],"experts\u2019":[96],"panel.":[97],"Unitary":[98],"costs":[99,136,206,214,218],"extracted":[101],"national":[103],"official":[104],"sources":[105],"expressed":[107],"2015":[109],"euros.":[110],"Incremental":[111],"per":[113],"quality":[114,174],"adjusted":[115,175],"life":[116,176],"years":[117,177],"gained":[118,190],"estimated":[120,186],"for":[121,135,151,162,166,248,256,272],"a":[122,130,152,158,249],"lifetime":[123,153],"horizon":[124],"societal":[127,149],"perspective,":[128,150],"assuming":[129],"3.5%":[131],"annual":[132],"discount":[133],"rate":[134],"consequences.":[138],"Deterministic":[139],"probabilistic":[141],"sensitivity":[142,227],"analyses":[143],"performed.":[145],"Results:":[146],"From":[147],"horizon,":[154],"predicted":[157],"\u20ac241,957":[161],"\u20ac223,903":[165],"care,":[168],"resulting":[169],"12.32":[171],"11.55":[173],"(QALY),":[178],"respectively.":[179],"Thus,":[180],"incremental":[182,229],"ratio":[184],"is":[185,260,280],"be":[188],"\u20ac23,332/QALY":[189],"(or":[191],"\u20ac35,225/QALY":[192],"National":[196],"Health":[197],"System":[198],"perspective).":[199],"Patients":[200],"receiving":[201,222],"incurred":[203],"more":[204],"(+\u20ac39,243),":[207],"partially":[208],"offset":[209],"less":[211],"direct":[212],"medical":[213],"(-\u20ac13,130)":[215],"indirect":[217],"(-\u20ac7,877)":[219],"than":[220],"In":[225],"deterministic":[226],"analyses,":[228],"ratios":[231],"ranged":[232],"between":[233],"\u20ac1,347":[234],"(0%":[235],"discount)":[236],"\u20ac42,465":[238],"(utilities\u2019":[239],"assumption).":[240],"The":[241],"probability":[242],"adalimumab\u2019s":[244],"61.2%":[247],"willingness-to-pay":[250],"threshold":[251],"\u20ac30,000":[253],"78%":[255],"\u20ac50,000.":[257],"Conclusion:":[258],"Adalimumab":[259],"first":[262],"only":[264],"drug":[265],"approved":[266],"European":[269],"Medicines":[270],"Agency":[271],"Hidradenitis":[273],"Suppurativa":[274],"its":[276],"Portugal":[279],"demonstrated":[281],"this":[283],"economic":[284],"analysis.":[285]},"counts_by_year":[],"updated_date":"2026-10-19T09:35:57.686232","created_date":"2018-10-26T00:00:00"}